Avanir To File Neurodex NDA For Pseudobulbar Affect By End Of 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will request priority review for the dextromethorphan/quinidine combination. A broad indication covering PBA (uncontrollable laughing/crying) in a range of neurological diseases is expected based on an agreement with FDA.